Dementia and Alzheimer Disease

Epilepsy

Headache and Migraine

Movement Disorders

Multiple Sclerosis

Neuromuscular

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

International Journal of MS Care

Resources

Disease Spotlight

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

eNewsletter

Print Subscription

Articles

The chief of the Movement Disorders Division at Mass General Hospital provided context on the goals behind the research careers reimagined course at the recently concluded ANA Annual Meeting.

NeuroVoices: Craig Blackstone, MD, PhD, FANA, on Helping Path Research Careers for Young Medical Professionals

Coya Therapeutics expects to release data from the biomarker analyses of COYA 302 and publish the full results from the trial in a peer-reviewed journal in the second half of the year.

Coya Therapeutics Announces Plans for FDA Discussion on ALS Agent COYA 302

Although research supports the use of physical therapy as an effective treatment for Parkinson disease, implementation factors including type, timing, frequency, and durability of outcomes remain mainly untouched.

Standard and Nonstandard Physical Therapy Show Similar Effectiveness for Parkinson Disease

Videos

The associate professor of neurology at Vanderbilt University Medical Center discussed the progress in stroke care, focusing on ischemic strokes and cerebral hemorrhages, and their connection with vascular diseases and cognitive disorders. [WATCH TIME: 3 minutes] 

Advancements in Stroke Care, Ischemic Stroke, and Cerebral Hemorrhages: Matthew Schrag, MD, PhD

Slideshows

Review the latest peer-reviewed articles dedicated to the multidisciplinary management of multiple sclerosis published in the International Journal of MS Care.

IJMSC September/October 2023 Highlights

, has been with the team since September 2022. Follow her on Twitter 

Leigh Charvet, PhD, professor of neurology at the NYU Grossman School of Medicine, talked about a trial that aims to address cognitive impairment in patients with long COVID through a unique, remote, and home-based treatment approach.

Targeting Cognitive Impairment of Long COVID With Brain Stimulation 

A panel of neurology experts detailed the importance that community leadership and creating a positive environment can do for patients with rare neurologic disorders [WATCH TIME: 5 minutes]

Role of Advocacy Organizations in Creating Safe Spaces for Rare Disorders

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

Twitter

LinkedIN

Spotlight

Ataxia

MDS 2023

NMOSD

Narcolepsy

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

's Future Leaders in Neurology seeks to connect the next generation of up-and-coming neurologists, advanced practice providers, and other healthcare professionals with individuals who have cultivated a range of clinical experiences. Together, they will share insights and perspectives to help mold the key thought leaders of tomorrow.

Leaders in Neurology

1rem

Experts in neurology discuss ongoing studies surrounding the use of BTK inhibitors and the role they are likely to play in the future treatment of multiple sclerosis.

Multiple Sclerosis Treatments on the Horizon: BTK Inhibitors

Ahmed Obeidat, MD, PhD; Benjamin Greenberg, MD; and Hesham Abboud, MD, discuss the prevelance of multiple sclerosis and comment on the mechanisms of action and available drug classes utilized in disease management.

Overview and Prevalence of Multiple Sclerosis (MS)

Drs Hesham Abboud and Benjamin Greenberg share their approach to treatment selection and highlight the importance of individualizing treatment and patient education.

Treatment Selection in Multiple Sclerosis Management

Experts in neurology comment on the factors they consider when selecting and sequencing treatments for their patients with multiple sclerosis. 

Treatment Sequencing in Multiple Sclerosis

Benjamin Greenberg, MD, hypthothezies on where BTK inhibitors fit into the current treatment algorithim for the management of patients with multiple sclerosis.

BTK Inhibitors in Multiple Sclerosis

Hesham Abboud, MD, provides insight into the impact of the differnet biochemical compositions of the currently investigated BTKis and highlights on-going clinical trials.

Progressive Multiple Sclerosis and BTK Inhibitors

Experts in neurology discuss safety concerns and considerations with the use of BTKis in the management of patients with multiple sclerosis.

BTKi Safety Considerations in Multiple Sclerosis

Dr Hesham Abboud shares his opinion on the clinical practicalities of BTKi utilization in patients with multiple sclerosis. 

 Using BTK Inhibitors in Clinical Practice for MS Management

Ahmed Obeidat, MD, PhD; Benjamin Greenberg, MD; and Hesham Abboud, MD, comment on the need for more inclusive clinical trial patient enrollment criteria, highlighting underserved patient populations.

Unmet Needs in Multiple Sclerosis Clinical Trial Design

Experts in neurology debate the utility of combination therapy in the management of multiple sclerosis and highlight current obstacles to this treatment approach both in clinical investigation and practice.

Role of Combination Therapy in Multiple Sclerosis

Drs Ahmed Obeidat, Hesham Abboud, and Benjamin Greenberg share their experiences with patient compliance and the route of administration of current and emerging therapies for multiple sclerosis.

Impact of Route of MS Treatment Administration on Adherence

Ahmed Obeidat, MD, PhD; Benjamin Greenberg, MD; and Hesham Abboud, MD, discuss their future hopes and concerns for the use of BTK inhibitors in the treatment of multiple sclerosis. 

Future Thoughts on BTK Inhibitors in Multiple Sclerosis

Drs Hesham Abboud and Benjamin Greenberg share their excitement for the future of multiple scelrosis treatment and comment on emerging therapies and novel mechanisms of action.

Novel Mechanisms of Action for Multiple Sclerosis Treatment

Ahmed Obeidat, MD, PhD; Benjamin Greenberg, MD; and Hesham Abboud, MD, share their hopes about the evolution of future mutiple sclerosis care and express their gratitude for the next generation of neurologists. 